Medifast stock hits 52-week low at $12.8 amid sharp decline

Published 04/04/2025, 16:14
Medifast stock hits 52-week low at $12.8 amid sharp decline

In a challenging year for Medifast (NYSE:MED) Inc., the company’s stock has tumbled to $12.57, near its 52-week low of $12.87. According to InvestingPro analysis, despite maintaining impressive gross profit margins of 73.8% and a healthy current ratio of 3.34, the stock has struggled. This significant drop reflects a broader trend for the weight-loss brand, which has seen its shares plummet by 61.45% over the past year, falling from a 52-week high of $36.30. Investors have been wary as the company grapples with market pressures and competitive challenges, leading to a stark decrease in shareholder value. The current price level represents a critical juncture for Medifast, as it strives to regain its footing and reassure stakeholders of its long-term strategy and growth potential. InvestingPro’s Fair Value analysis suggests the stock may be undervalued at current levels. Discover 12 more exclusive ProTips and comprehensive analysis with an InvestingPro subscription.

In other recent news, Medifast reported its fourth-quarter 2024 earnings with a mixed financial performance. The company exceeded earnings per share (EPS) expectations, achieving $0.10 compared to a forecasted -$0.14, but missed revenue forecasts, reporting $119 million against an expected $131.65 million. This represented a significant 37.7% year-over-year revenue decline. Meanwhile, Medifast maintained a strong cash position with $162.3 million and no debt, highlighting its financial stability despite the challenges. DA Davidson maintained a Neutral rating on Medifast shares but slightly reduced the price target from $17.00 to $16.50. This adjustment followed Medifast’s earnings report, which showed signs of improvement in sales per Coach (NYSE:TPR) for the third consecutive quarter. The company recently launched the Ascend product line, aimed at users of GLP-1 weight loss drugs, which has been well-received. Medifast’s guidance for the first quarter of 2025 anticipates revenue between $100 million and $120 million, with EPS guidance ranging from $0 to -$0.50.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.